Janssen Pharma. Inc. et al. v. Teva Pharma. USA Inc.

On behalf of Janssen Pharmaceuticals and its affiliate – the plaintiffs in a patent infringement action brought against Teva Pharmaceuticals USA – a team from Analysis Group, led by Vice President Kate Schofield, provided research and analytical support to Managing Principal Carla S. Mulhern, who testified at trial regarding the commercial success of Janssen’s patent for Invega Sustenna® (paliperidone palmitate). Analysis Group was retained by the law firm Patterson Belknap Webb & Tyler in the case.

Teva filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) seeking to market a generic version of Invega Sustenna, Janssen’s long-acting injectable (LAI) used in the treatment of schizophrenia and schizoaffective disorder. Ms. Mulhern’s testimony assisted the Court in evaluating the commercial success of Janssen’s product by analyzing economic issues related to the marketplace success of Invega Sustenna as well as the nexus between that success and the patent-in-suit.

The Honorable Claire C. Cecchi, a Judge in the U.S. District Court for the District of New Jersey, cited Ms. Mulhern’s testimony in her opinion, which ruled in favor of Janssen, concluding that it had demonstrated the commercial success of Invega Sustenna.